Effect and Safety of Dapagliflozin Combined with Linagliptin in Obese Patients with Type 2 Diabetes Mellitus
Objective To analyze the effect of dapagliflozin combined with linagliptin in the treatment of obese patients with type 2 diabetes mellitus.Methods A total of 80 obese patients with type 2 diabetes mellitus admitted to our hospital from June 2021 to June 2023 were selected as the research objects.They were divided into control group(n=40)and study group(n=40)according to the random number table method.The control group was treated with linagliptin,and the study group was treated with linagliptin on the basis of the control group.The blood glucose indexes[fasting blood glucose(FPG),glycosylated hemoglobin(HbA1c),insulin resistance index,blood lipid indexes[total cholesterol(TC),triglyceride(TG)],renal function indexes[urinary microalbumin(UAlb),urinary albumin/creatinine ratio(UACR),serum creatinine concentration(SCr)]and incidence of adverse reactions were compared between the two groups.Results The insulin resistance index of the two groups after treatment was lower than that before treatment,and that of the study group was lower than that of the control group(P＜0.05).After treatment,FPG and HbA1 c in the two groups were lower than those before treatment,and those in the study group were lower than the control group(P＜0.05).There was no significant difference in TC and TG levels between the two groups before and after treatment(P＞0.05).After treatment,UAlb,UACR and SCr in the two groups were lower than those before treatment,and those in the study group were lower than the control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the study group and the control group(P＞0.05).Conclusion Dapagliflozin combined with linagliptin is effective in obese patients with type 2 diabetes mellitus,which can effectively control blood glucose index,improve renal function,reduce insulin resistance,and will not increase adverse reactions.It is an effective and reliable treatment plan.
DapagliflozinLigliptinObesity type 2 diabetes mellitusInsulin resistance index
万方数据
维普
